Briefing
FDA lists FoundationOne CDx and FoundationOne Liquid CDx for HRR selection of talazoparib plus enzalutamide
The FDA companion-diagnostic list dated May 27, 2026 includes FoundationOne CDx (P170019/S060) and FoundationOne Liquid CDx (P190032/S029) to identify homologous-recombination-repair gene alterations for talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer.